Carbapenem Resistant Pseudomonas aeruginosa Infections in Elderly Patients: Antimicrobial Resistance Profiles, Risk Factors and Impact on Clinical Outcomes
Jie Qin,Chengyun Zou,Jianmin Tao,Tian Wei,Li Yan,Yufei Zhang,Haiying Wang,Yufei Zhang Zhang
DOI: https://doi.org/10.2147/IDR.S358778
2022-04-29
Infection and Drug Resistance
Abstract:Jie Qin, 1, 2 Chengyun Zou, 2 Jianmin Tao, 1 Tian Wei, 1 Li Yan, 1 Yufei Zhang, 2 Haiying Wang 1 1 Department of Clinical Laboratory, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Department of Medical Technology, Yueyang Clinical Medical College, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China Correspondence: Haiying Wang, Email Objective: The prevalence and clinical impact on mortality of carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection are unclear in elderly patients. Here, we aimed to clarify the prevalence, the clinical manifestations, antimicrobial resistance, risk factors and outcomes of elderly inpatients with CRPA infection. Methods: A retrospective study of 600 elderly inpatients infected with P. aeruginosa was conducted at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine from January 1st 2018 to December 31st 2020. All 155 patients with CRPA infection were designated as a case group. Patients with carbapenem-susceptible Pseudomonas aeruginosa (CSPA) were randomly selected from remaining 445 cases in a 1:1 ratio to case group as a control group. Results: Of 600 P. aeruginosa isolates, the overall rates of CRPA, MDR PA (multidrug-resistance Pseudomonas aeruginosa ) were 25.8% (155), 22.3% (134), respectively. The rankings of the top five resistant rates of CRPA to tested antimicrobial drugs were imipenem (87.7%), meropenem (70.3%), ciprofloxacin (51.0%), levofloxacin (48.4%), cefoperazone (43.2%). Independent risk factors for patients with CRPA infection were cerebrovascular disease (OR = 3.517, P < 0.001), foley catheter (OR = 2.073, P = 0.018), length of hospital stay ≥ 14 days (OR = 1.980, P = 0.013), albumin < 35 g/L (OR = 2.049, P = 0.020), previous antibiotic exposure to carbapenems (OR = 7.022, P = 0.004), previous antibiotic exposure to third- or fourth-generation cephalosporins (OR = 12.649, P = 0.002). Of 155 patients with CRPA infection, the mortality rate was 16.8% (26/155). Independent risk factors for mortality were receiving mechanical ventilation (OR = 3.671, P = 0.007) and neutrophil percentage ≥ 80% (OR = 2.908, P = 0.024). Conclusion: The study revealed high rates of CRPA, MDR PA among the hospitalized elderly patient with P. aeruginosa infection. The analysis of antimicrobial susceptibility emphasizes the necessity for antimicrobial stewardship and infection control in hospitals. These findings of risk factors are practical significant to identify patients at high risk for CRPA infection and mortality that may benefit from alternate empiric treatment. Keywords: Pseudomonas aeruginosa , carbapenem-resistant, infection, mortality, risk factors Pseudomonas aeruginosa ( P. aeruginosa ) is an important nosocomial pathogen that causes a wide spectrum of infections, such as pneumonia, urinary tract infections, surgical site infections, and bloodstream infections. 1 In 2020, surveillance of nosocomial infections in China showed that P. aeruginosa was the fourth most frequently isolated Gram-negative bacilli, accounting for 8.4% of hospital-acquired infections in China Antimicrobial Surveillance Network (CHINET). 2 Infections caused by P. aeruginosa isolates are typically difficult to treat and eradicate due to intrinsic antibiotic resistance and a remarkable ability to acquire resistance to multiple groups of antimicrobial agents. 3 Recent years have witnessed an increasing prevalence of multidrug-resistant (MDR) and extensively-resistant (XDR) P. aeruginosa strains, with rates of between 15% and 30% in some geographical areas. 4–6 Carbapenem antibiotics reserved as agents of last resort for P. aeruginosa strains that are resistant to first-line broad-spectrum antibiotics were introduced to treat serious MDR P. aeruginosa (MDRPA) infections but eventually led to a soaring of carbapenem-resistant isolates around the global. 7 In 2017, the World Health Organization placed CRPA as a critical priority pathogen that desperately requires new treatment options. 8 The successful worldwide spread of the so-called "high-risk" clones of P. aeruginosa poses a threat to global public health that needs to be studied and managed with urgency and determination. Patients with infections due to CRPA pathogens usually lead to worse clinical outcomes and higher mor -Abstract Truncated-
pharmacology & pharmacy,infectious diseases